Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03803436
Other study ID # INT 108/18
Secondary ID
Status Recruiting
Phase Phase 2
First received
Last updated
Start date January 2, 2019
Est. completion date January 2024

Study information

Verified date March 2023
Source Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Contact Vincenzo Mazzaferro, MD, PhD
Phone +39 02 23902760
Email segreteria.mazzaferro@istitutotumori.mi.it
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The COLT trial is an investigator-driven, multicenter, non-randomized, open-label, controlled, prospective, parallel trial, aimed at assessing the efficacy (in terms of overall survival: OS) of liver transplantation (LT) in liver-only CRC metastases, compared with a matched cohort of patients bearing the same tumor characteristics, collected during the same time period and included in a phase III Italian RCT on triplet chemotherapy+antiEGFR


Recruitment information / eligibility

Status Recruiting
Enrollment 22
Est. completion date January 2024
Est. primary completion date January 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years to 69 Years
Eligibility Inclusion Criteria: - Histologically confirmed non-mucinous colon adenocarcinoma. - Primary tumor as pT1-3, pN0 or pN1 (metastases in < 4 regional lymph nodes), confirmed R0 resection. - RAS and BRAF wild-type & MSS molecular status as per local testing. - Liver metastases not eligible for curative liver resection - Objective response according to RECIST 1.1 to first-line treatment, with sustained response for at least 4 months, OR disease control (CR+PR+SD) during second-line treatment for at least 4 months. - A maximum of two prior chemotherapy treatment lines. - Performance status, ECOG 0. - Satisfactory blood tests Hb >10g/dl, neutrophils >1.0 (after any G-CSF), TRC >75, Bilirubin<2 x upper normal level, AST, ALT<5 x upper normal level, creatinine <1.25 x upper normal level. - CEA<50 ng/ml Exclusion Criteria: - Hereditary CRC syndromes including FAP and Lynch syndrome. - Prior extra hepatic metastatic disease or primary tumor local relapse. - Extra-peritoneal cancers (rectum). - Other malignancies in the previous 5 years - Active intra-venous or alcohol abusers - HIV infection

Study Design


Intervention

Procedure:
Liver transplant
Liver transplant from cadaveric donors
Drug:
Chemotherapy
mFOLFOX
Chemotherapy
Panitumumab

Locations

Country Name City State
Italy SOD Clinica di Chirurgia Epatobiliare, Pancreatica e dei Trapianti e SC di Oncologia Medica, Ospedali Riuniti di Ancona Ancona
Italy ASST Papa Giovanni XXIII Bergamo
Italy Chirurgia EBP e dei Trapianti di Fegato e SC di Oncologia Medica, Ospedale Policlinico San Martino Genova
Italy Fondazione IRCCS Istituto NAzionale Tumori di Milano Milan
Italy Azienda Ospedaliera Ospedale Niguarda Ca' Granda Milano
Italy Ospedale Maggiore di Milano Policlinico Milano
Italy Istituto Mediterraneo per i Trapianti e Terapie ad Alta Specializzazione (ISMETT) Palermo
Italy GONO Group (Gruppo Oncologico Nord Ovest) TRIPLETE Trial Coordination Pisa
Italy Fondazione Policlinico Universitario A.Gemelli IRCCS Roma
Italy Ospedale Universitario Molinette S. Giovanni Battista di Torino Torino
Italy Centro Trapianti di Fegato e SC di Oncologia Medica, A.S.U. Integrata di Udine Udine
Italy Centro Trapianti di Fegato e SC di Oncologia Medica, A.O.U. Integrata di Verona Verona

Sponsors (3)

Lead Sponsor Collaborator
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano Gruppo Oncologico del Nord-Ovest, Istituto Di Ricerche Farmacologiche Mario Negri

Country where clinical trial is conducted

Italy, 

Outcome

Type Measure Description Time frame Safety issue
Primary Overall Survival Time from enrolement to either death or censoring 5 years
Secondary Progression Free Survival Time from enrolement to either progression or censoring 5 years
Secondary Complications rate Complications according to Dindo Clavien Classification 90 days after liver transplant
See also
  Status Clinical Trial Phase
Completed NCT03826043 - THrombo-Embolic Event in Onco-hematology N/A
Terminated NCT03166631 - A Trial to Find the Safe Dose for BI 891065 Alone and in Combination With BI 754091 in Patients With Incurable Tumours or Tumours That Have Spread Phase 1
Completed NCT01938846 - BI 860585 Dose Escalation Single Agent and in Combination With Exemestane or With Paclitaxel in Patients With Various Advanced and/or Metastatic Solid Tumors Phase 1
Recruiting NCT06058312 - Individual Food Preferences for the Mediterranean Diet in Cancer Patients N/A
Completed NCT03308942 - Effects of Single Agent Niraparib and Niraparib Plus Programmed Cell Death-1 (PD-1) Inhibitors in Non-Small Cell Lung Cancer Participants Phase 2
Recruiting NCT06018311 - Exercising Together for Hispanic Prostate Cancer Survivor-Caregiver Dyads N/A
Withdrawn NCT05431439 - Omics of Cancer: OncoGenomics
Completed NCT01343043 - A Pilot Study of Genetically Engineered NY-ESO-1 Specific NY-ESO-1ᶜ²⁵⁹T in HLA-A2+ Patients With Synovial Sarcoma Phase 1
Completed NCT01938638 - Open Label Phase I Dose Escalation Study With BAY1143572 in Patients With Advanced Cancer Phase 1
Recruiting NCT05514444 - Study of MK-4464 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced/Metastatic Solid Tumors (MK-4464-001) Phase 1
Recruiting NCT02292641 - Beyond TME Origins N/A
Terminated NCT00954512 - Study of Robatumumab (SCH 717454, MK-7454) in Combination With Different Treatment Regimens in Participants With Advanced Solid Tumors (P04722, MK-7454-004) Phase 1/Phase 2
Recruiting NCT04958239 - A Study to Test Different Doses of BI 765179 Alone and in Combination With Ezabenlimab in Patients With Advanced Cancer (Solid Tumors) Phase 1
Recruiting NCT04627376 - Multimodal Program for Cancer Related Cachexia Prevention N/A
Completed NCT01222728 - Using Positron Emission Tomography to Predict Intracranial Tumor Growth in Neurofibromatosis Type II Patients
Recruiting NCT06004440 - Real World Registry for Use of the Ion Endoluminal System
Active, not recruiting NCT05636696 - COMPANION: A Couple Intervention Targeting Cancer-related Fatigue N/A
Not yet recruiting NCT06035549 - Resilience in East Asian Immigrants for Advance Care Planning Discussions N/A
Recruiting NCT06004466 - Noninvasive Internal Jugular Venous Oximetry
Completed NCT03190811 - Anti-PD-1 Alone or Combined With Autologous DC-CIK Cell Therapy in Advanced Solid Tumors Phase 1/Phase 2